Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

13 Going On 50: Pfizer Seeks Adult Indication For Prevnar

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee might closely scrutinize the requested indication for the 13-valent pneumococcal conjugate vaccine for adults age 50 and up; it is now indicated for children under six years old.
Advertisement

Related Content

Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound
2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound
ACIP Support Of FDA-Approved Prevnar 13 Creates Prospect For Larger Market
Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok
Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok
No Non-Inferiority, No Problem: FDA Advisory Committee Endorses Prevnar 13

Topics

Advertisement
UsernamePublicRestriction

Register

PS071646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel